3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Lymphoid
2
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
299
Radiotherapy
219
Bevacizumab
139
Carboplatin
91
Cyclophosphamide
88
Etoposide
82
Filgrastim
72
Vincristine
69
Irinotecan
69
Magnetic Resonance Spectroscopy
65
Cisplatin
59
Radiation
58
Radiosurgery
52
Surgical Procedures, Operative
41
Peripheral Blood Stem Cell Transplantation
40
Topotecan
39
Doxorubicin
39
Lomustine
37
Carmustine
36
sargramostim
35
Granulocyte Colony-Stimulating Factor
35
Melphalan
34
Nivolumab
32
Chemotherapy, Adjuvant
32
Radiotherapy, Intensity-Modulated
29
Isotretinoin
29
Everolimus
29
Erlotinib Hydrochloride
27
Thiotepa
25
Vorinostat
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
interferon gamma-1b
×
CNS
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled